2023年
(4) Mansell1, J. P.; Tanatani, A.; Kagechika, H. An N-cyanoamide derivative of lithocholic acid co-operates with lysophosphatidic acid to promote human osteoblast (MG63) differentiation.
Biomol. 2023, 13, 1113.
DOI: 10.3390/biom13071113
(3) Qin, X.-Y.; Furutani, Y.; Yonezawa, K.; Shimizu, N.; Kato-Murayama, M.; Shirouzu, M.; Xu, Y.; Yamano, Y.; Wada, A.; Gailhouste, L.; Shrestha, R.; Takahashi, M.; Keillor, J. W.; Su, T.; Yu, W.; Fujii, S.; Kagechika, H.; Dohmae, N.; Shirakami, Y.; Shimizu, M.; Masaki, T.; Matsuura, T.; Suzuki, H.; Kojima, S.
Targeting transglutaminase 2 mediated exostosin glycosyltransferase 1 signaling in liver cancer stem cells with acyclic retinoid.
Cell Death Disease 2023, 14, 358.
DOI: 10.1038/s41419-023-05847-4
(2)Regulation of Thrombin Activity by Ligand-Induced Topological Alteration in Thrombin-Binding Aptamer
Shogo Sasaki, Yue Ma, Takatsugu Hirokawa, Kazunori Ikebukuro, Masayuki Tera, Kazuo Nagasawa
Chem. Commun. 2023, 59 , 8862.
DOI: 10.1039/D3CC02308G
(1) Targeting Cellular Retinoic Acid Binding Protein 1 with Retinoic Acid-like Compounds to Mitigate Motor Neuron Degeneration.
Nhieu, J.; Milbauer, L.; Lerdall, T.; Najjar, F.; Wei, C.-W.; Ishida, R.; Ma, Y.; Kagechika, H.; Wei, L.-N.
Int. J. Mol. Sci. 2023, 24, 4980.
DOI: 10.3390/ijms24054980
2022年
(9) A Novel Lithocholic Acid Derivative Upregulates Detoxification-Related Genes in Human Induced Pluripotent Stem Cell-Derived Intestinal Organoids.Yamada, S.; Masuno, H.; Kagechika, H.; Tanatani, H.; Kanda, Y.
Biol. Pharm. Bull. 2022, 45, 1720-1724.
DOI: 10.1248/bpb.b22-00492
(8) Development of a water-soluble ryanodine receptor 1 inhibitor
Ryosuke Ishida, Shuichi Mori, Takashi Murayama, Ayaka Nakamichi, Xikun Chai, Nagomi Kurebayashi, Hiroto Iinuma, Hiroyuki Kagechika
Bioorg. Med. Chem. 2022, 74, 117027.
DOI: 10.1016/j.bmc.2022.117027
(7) A reconstituted depolarization-induced Ca2+ release platform for validation of skeletal muscle disease mutations and drug discovery
Takashi Murayama, Nagomi Kurebayashi, Takuro Numaga-Tomita, Takuya Kobayashi, Satoru Okazaki, Kyosuke Yamashiro, Tsutomu Nakada, Shuichi Mori, Ryosuke Ishida, Hiroyuki Kagechika, Mitsuhiko Yamada, Takashi Sakurai
J. Gen. Physiol. 2022, 154, e202213230.
DOI: 10.1085/jgp.202213230
(6) Mice with R2509C-RYR1 mutation exhibit dysfunctional Ca2+ dynamics in primary skeletal myocytes
Yoshitaka Tsuboi, Kotaro Oyama, Fuyu Kobirumaki-Shimozawa, Takashi Murayama, Nagomi Kurebayashi, Toshiaki Tachibana, Yoshinobu Manome, Emi Kikuchi, Satoru Noguchi, Takayoshi Inoue, Yukiko U. Inoue, Ichizo Nishino, Shuichi Mori, Ryosuke Ishida, Hiroyuki Kagechika, Madoka Suzuki, Norio Fukuda, Toshiko Yamazawa
J. Gen. Physiol. 2022, 154, e202213136.
DOI: 10.1085/jgp.202213136
(5) Development of retinoic acid receptor antagonists bearing trans-SF4-alkynyl structure as a linear linker.
Mori, S.; Tsuemoto, N.; Kawachi, E.; Takubo, C.; Tanatani, A.; Kagechika, H.
Tetrahedron 2022, 123, 132967.
DOI: 10.1016/j.tet.2022.132967.
(4) LRBA is essential for urinary concentration and body water homeostasis.
Hara, Y.; Ando, F.; Oikawa, D.; Ichimura, K.; Yanagawa, H.; Sakamaki, Y.; Nanamatsu, A.; Fujiki, T.; Mori, S.; Suzuki, S.; Yui, N.; Mandai, S.; Susa, K.; Mori, T.; Sohara, E.; Rai, T.; Takahashi, M.; Sasaki, S.; Kagechika, H.; Tokunaga, F.; Uchida, S.
Proc. Natl. Acad. Sci. 2022, 119, e2202125119.
DOI: 10.1073/pnas.2202125119
(3) Structural Development of Silicon-Containing Retinoids: Structure–Activity Relationship Study of the Hydrophobic Pharmacophore of Retinobenzoic Acids Using Silyl Functionalities.
Oikawa, T.; Fujii, S.; Mori, S.; Masuno, H.; Kawachi, E.; Kagechika, H.
ChemMedChem 2022, 17, e202200176.
DOI: 10.1002/cmdc.202200176
(2) Lithocholic Acid Amides as Potent Vitamin D Receptor Agonists.
Yoshihara, A.; Kawasaki, H.; Masuno, M.; Takada, K.; Numoto, N.; Ito, N.; Hirata, N.; Kanda, Y.; Ishizawa, M.; Makishima, M.; Kagechika, H.; Tanatani, A.
Biomol. 2022, 12, 130.
DOI: 10.3390/biom12010130
(1) Design, synthesis and structure–activity relationship of 4-(1,1,1,3,3,3-hexafluoro-2-hydroxyisoprop-2-yl)phenylsilane derivatives as liver X receptor agonists.
Namba, N.; Noguchi-Yachide, T.; Matsumoto, Y.; Hashimoto, Y.; Fujii, S.
Bioorg. Med. Chem. 2022, 66, 116792.
DOI: 10.1016/j.bmc.2022.116792
2021年
(14) ASKA technology-based pull-down method reveals a suppressive effect of ASK1 on the inflammatory NOD-RIPK2 pathway in brown adipocytes.Takayanagi, S.; Watanabe, K.; Maruyama, T.; Ogawa, M.; Morishita, K.; Soga, M.; Hatta, T.; Natsume, T.; Hirano, T.; Kagechika, H.; Hattori, K.; Naguro, I.; Ichijo, H.
Sci. Rep. 2021, 11, 22009.
DOI: 10.1038/s41598-021-01123-7
(13) Structural Development of Salicylanilide-Based SPAK Inhibitors as Candidate Antihypertensive Agents.
Fujii, S.; Kikuchi, E.; Suzuyama, H.; Watanabe, Y.; Ishigami-Yuasa, M.; Masuno, H.; Mori, T.; Isobe, K.; Uchida, S.; Kagechika, H.
ChemMedChem 2021, 16, 2817-2822.
DOI: 10.1002/cmdc.202100273
(12) Identification of a KLF5-dependent program and drug development for skeletal muscle atrophy.
Liu, L.; Koike, H.; Ono, T.; Hayashi, S.; Kudo, F.; Kaneda, A.; Kagechika, H.; Manabe, I.; Nakashima, T.; Oishi. Y.
Proc. Natl. Acad. Sci. USA 2021, 118, e2102895118.
DOI: 10.1073/pnas.2102895118
(11) A novel RyR1-selective inhibitor prevents and rescues sudden death in mouse models of malignant hyperthermia and heat stroke.
Konishi, M.; Noguchi, S.; Inoue, T.; Inoue, Y. U.; Nishino, I.; Mori, S.; Iinuma, H.; Manaka, N.; Kagechika, H.; Uryash, A.; Adams, J.; Lopez, J. R.; Liu, X. C.; Diggle, C.; Allen, P. D.; Kakizawa, S.; Ikeda, K.; Lin, B. Z.; Ikemi, Y.; Nunomura, K.; Nakagawa, S.; Sakurai, T.; Murayama, T.
Nat. Commun. 2021, 12, 4293.
DOI: 10.1038/s41467-021-24644-1
(10) CSE1L promotes nuclear accumulation of transcriptional coactivator TAZ and enhances invasiveness of human cancer cells.
Osada, H.; Nawa, M.; Nakahama, K.; Ishigami-Yuasa, M.; Kagechika, H.; Sugimura, H.; Iwasa, H.; Arimoto-Matsuzaki, K.; Nishina, H.; Hata, Y.
J. Biol. Chem. 2021, 297, 100803.
DOI: 10.1016/j.jbc.2021.100803
(9) Regulation of exosome secretion by cellular retinoic acid binding protein 1 contributes to systemic anti-inflammation.
Lin, Y.-W.; Nhieu, J.; Wei, C.-W.; Lin, Y.-L.; Kagechika, H.; Wei, L.-N.
Cell Commun. Signal. 2021, 19, 69.
DOI: 10.1186/s12964-021-00751-w
(8) Synthesis and Structure-Activity Relationship Study of 1,12-Dicarba-closo-dodecaborane-based Triol Derivatives as Nonsecosteroidal Vitamin D Analogs.
Fujii, S.; Sekine, R.; Kano, A.; Masuno, H.; Kawachi, E.; Hirano, T.; Kagechika, H.
Heterocycles 2021, 103, 444-458.
DOI: 10.3987/COM-20-S(K)30
(7) Structure-property and structure–activity relationships of phenylferrocene derivatives as androgen receptor antagonists
Ochiai, K.; Fujii, S.
Bioorg. Med. Chem. Lett. 2021, 46, 128141.
DOI: 10.1016/j.bmcl.2021.128141
(6) Design, synthesis and antitumor activity of phthalazine-1,4-dione-based menaquinone analogs.
Fujii, S.; Miura, T.; Oikawa, T.; Qin, X.-Y.; Kojima, S.; Kagechika, H.
Bioorg. Med. Chem. Lett. 2021, 43, 128065.
DOI: 10.1016/j.bmcl.2021.128065
(5) 6-Arylcoumarin as a Scaffold of Photofunctional Molecules with OFF-ON-OFF Type Regulation.
Kato, D.; Shiraishi, T.; Kagechika, H.; Hirano, T
J. Org. Chem. 2021, 86, 2264-2270.
DOI: 10.1021/acs.joc.0c02419
(4) Pharmacophore-guided repurposing of fibrates and retinoids as GPR40 allosteric ligands with activity on insulin release.
Cione, E.; Caroleo, M. C.; Kagechika, H.; Manetti, F.
J. Enzyme Inhibit. Med. Chem. 2021, 36, 377-383.
DOI: 10.1080/14756366.2020.1864629
(3) Construction of Aromatic Multilayered Structures Based on the Conformational Properties of N,N’-Dimethylated Squaramide.
Arimura, M.; Tanaka, K.; Kanda, M.; Urushibara, K.; Fujii, S.; Katagiri, K.; Azumaya, I.; Kagechika, H.; Tanatani, A.
ChemPlusChem. 2021, 86, 198-205.
DOI: 10.1002/cplu.202000678
(2) Lithocholic Acid Derivatives as Potent Vitamin D Receptor Agonists.
Sasaki, H.; Masuno, H.; Kawasaki, H.; Yoshihara, A.; Numoto, N.; Ito, N.; Ishida, H.; Yamamoto, K.; Hirata, N.; Kanda, Y.; Kawachi, E.; Kagechika, H.; Tanatani, A.
J. Med. Chem. 2021, 64, 516-526.
DOI: 10.1021/acs.jmedchem.0c01420
(1) Activation of beta 2-adrenergic receptor signals suppresses mesenchymal phenotypes of oral squamous cell carcinoma cells.
Sakakitani, S.; Podyma-Inoue, K. A. ; Takayama, R.; Takahashi, K .; Ishigami-Yuasa, M.; Kagechika, H.; Harada, H.; Watabe, T.
Cancer Sci. 2021, 112, 155-167.
DOI: 10.1111/cas.14670
2020年
(7) WNK regulates Wnt signalling and beta-Catenin levels by interfering with the interaction between b-Catenin and GID.Sato, A.; Shimizu, M.; Goto, T.; Masuno, H.; Kagechika, H.; Tanaka, N. ; Shibuya, H.
Communications Biol. 2020, 3, 666.
DOI: 10.1038/s42003-020-01386-2
(6) Structural development of N-(4-phenoxyphenyl)benzamide derivatives as novel SPAK inhibitors blocking WNK kinase signaling.
Fujii, S.; Kikuchi, E.; Watanabe, Y.; Suzuyama, H.; Ishigami-Yuasa, M.; Mori, T.; Isobe, K.; Uchida, U.; Kagechika, H.
Bioorg. Med. Chem. Lett. 2020, 30, 127408.
DOI: 10.1016/j.bmcl.2020.127408
(5) Prostaglandin E-2 and its receptor EP2 trigger signaling that contributes to YAP-mediated cell competition.
Ishihara, E.; Nagaoka, Y.; Okuno, T.; Kofuji, S.; Ishigami-Yuasa, M.; Kagechika, H.; Kamimura, K.; Terai, S.; Yokomizo, T.; Sugimoto, Y.; Fujita, Y.; Suzuki, A.; Nishina, H.
Genes to Cells 2020, 25, 197-214.
DOI: 10.1111/gtc.12750
(4) Characterization of a novel compound that promotes myogenesis via Akt and transcriptional co-activator with PDZ-binding motif (TAZ) in mouse C2C12 cells.
Kodaka, M.; Arimoto-Matsuzaki, K.; Kitamura, M.; Xu, X.; Yang, Z.; Nakagawa, K.; Maruyama, J.; Ishii, K.; Akazawa, C.; Oyaizu, T.; Yamamoto, N.; Enomoto, M.; Ishigami-Yuasa, M.; Tsuemoto, N.; Ito, S.; Kagechika, H.; Nishina, H.; Hata, Y.
Plos ONE 2020, 15, e0231265.
DOI: 10.1371/journal.pone.0231265
(3) Development of Androgen-Antagonistic Coumarinamides with a Unique Aromatic Folded Pharmacophore.
Koga, H.; Negishi, M.; Kinoshita, M.; Fujii, S.; Mori, S.; Ishigami-Yuasa, M.; Kawachi, E.; Kagechika, H.*; Tanatani, A.*
Int. J. Mol. Sci. 2020, 21, 5584.
DOI: 10.3390/ijms21155584
(2) Development of Helical Aromatic Amide Foldamers with a Diphenylacetylene Backbone.
Urushibara, K.; Yamada, T.; Yokoyama, A.; Mori, H.; Masu, H.; Azumaya, I.; Kagechika, H.; Yokozawa, T.; Tanatani, A.
J. Org. Chem. 2020, 85, 2019-2039.
DOI: 10.1021/acs.joc.9b02758
(1) Phosphine boranes as less hydrophobic building blocks than alkanes and silanes: structure-property relationship and estrogen-receptor-modulating potency of 4-phosphinophenol derivatives
Saito, H.; Matsumoto, Y.; Hashimoto, Y.; Fujii, S.*
Bioorg. Med. Chem. 2020, 28, 115310.
DOI: 10.1016/j.bmc.2020.115310
2023年 (4)
2022年 (9)
2021年 (14)
2020年 (7)
薬化学分野
〒101-0062
東京都千代田区
神田駿河台2-3-10
生体材料工学研究所 6階
TEL 03-5280-8032
FAX 03-5280-8127